Bay Colony Advisory Group Inc d b a Bay Colony Advisors Sells 37,358 Shares of Pfizer Inc. (NYSE:PFE)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lowered its stake in Pfizer Inc. (NYSE:PFE) by 48.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,424 shares of the biopharmaceutical company’s stock after selling 37,358 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Pfizer were worth $1,164,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Worth Asset Management LLC bought a new stake in Pfizer during the first quarter worth $29,000. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter worth $30,000. GoalVest Advisory LLC raised its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter worth $34,000. Finally, VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 1st. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

Pfizer stock traded down $0.48 during trading hours on Friday, reaching $25.86. 43,034,056 shares of the stock were exchanged, compared to its average volume of 35,130,948. The company has a market cap of $146.43 billion, a P/E ratio of 71.83, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $41.71. The stock has a 50 day moving average of $27.28 and a two-hundred day moving average of $28.91.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.